IS8115A - Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra - Google Patents

Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra

Info

Publication number
IS8115A
IS8115A IS8115A IS8115A IS8115A IS 8115 A IS8115 A IS 8115A IS 8115 A IS8115 A IS 8115A IS 8115 A IS8115 A IS 8115A IS 8115 A IS8115 A IS 8115A
Authority
IS
Iceland
Prior art keywords
mcp
monoclonal antibody
directed against
antibodies directed
antibody protein
Prior art date
Application number
IS8115A
Other languages
English (en)
Inventor
M. Gudas Jean
Haak-Frendscho Mary
Foord Orit
L. Liang Meina
Ahluwalia Kiran
Bhakta Sunil
Original Assignee
Abgenix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31888391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenix, Inc. filed Critical Abgenix, Inc.
Publication of IS8115A publication Critical patent/IS8115A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8115A 2002-08-19 2005-11-01 Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra IS8115A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40480202P 2002-08-19 2002-08-19
PCT/US2003/026232 WO2004016769A2 (en) 2002-08-19 2003-08-19 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof

Publications (1)

Publication Number Publication Date
IS8115A true IS8115A (is) 2005-11-01

Family

ID=31888391

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8115A IS8115A (is) 2002-08-19 2005-11-01 Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra

Country Status (17)

Country Link
US (3) US7202343B2 (is)
EP (1) EP1542724A4 (is)
JP (1) JP4468172B2 (is)
AU (1) AU2003265575B2 (is)
CA (1) CA2496419A1 (is)
CO (1) CO6220978A2 (is)
HR (1) HRP20050986A2 (is)
IL (1) IL171674A0 (is)
IS (1) IS8115A (is)
LT (1) LT5416B (is)
ME (1) MEP18108A (is)
NZ (1) NZ542784A (is)
RS (1) RS20050834A (is)
RU (1) RU2339647C2 (is)
UA (1) UA87979C2 (is)
WO (1) WO2004016769A2 (is)
ZA (1) ZA200508994B (is)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575939B2 (en) 2000-10-30 2009-08-18 Sru Biosystems, Inc. Optical detection of label-free biomolecular interactions using microreplicated plastic sensor elements
US7118710B2 (en) * 2000-10-30 2006-10-10 Sru Biosystems, Inc. Label-free high-throughput optical technique for detecting biomolecular interactions
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
US7927822B2 (en) 2002-09-09 2011-04-19 Sru Biosystems, Inc. Methods for screening cells and antibodies
ATE394676T1 (de) 2003-03-12 2008-05-15 Rappaport Family Inst For Res Verbindungen und verfahren zur diagnose von prostatakrebs
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
EP1684703A4 (en) * 2003-11-05 2008-10-01 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH MCP-1
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US8481035B2 (en) * 2004-04-27 2013-07-09 Northwestern University Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A
US7794949B2 (en) * 2004-04-27 2010-09-14 Northwestern University Biomarkers of chronic pelvic pain syndrome
DE602005020799D1 (de) * 2004-08-05 2010-06-02 Genentech Inc Humanisierte anti-cmet-antagonisten
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
PE20110071A1 (es) * 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7713521B2 (en) * 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
US20080118437A1 (en) * 2006-03-01 2008-05-22 Regents Of The University Of Michigan Diagnosis and treatment O prostate cancer
US20080039340A1 (en) * 2006-05-26 2008-02-14 Steven Kornblau Reverse Phase Protein Array, Protein Activation and Expression Signatures, and Associated Methods
US20090297502A1 (en) * 2006-06-15 2009-12-03 Li Li Ccr2 antagonists for chronic organ transplantation rejection
ES2434039T3 (es) * 2006-07-24 2013-12-13 Yeda Research And Development Co. Ltd. Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
AU2007337983A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
EP1958647A1 (en) * 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
JP2011517548A (ja) * 2007-06-29 2011-06-16 セントコア・オーソ・バイオテツク・インコーポレーテツド 抗ｍｃｐ−１抗体、組成物、方法及び使用
WO2009009718A1 (en) 2007-07-11 2009-01-15 Sru Biosystems, Inc. Methods of identifying modulators of ion channels
US9134307B2 (en) 2007-07-11 2015-09-15 X-Body, Inc. Method for determining ion channel modulating properties of a test reagent
MX2010001395A (es) * 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2009028411A1 (ja) * 2007-08-24 2009-03-05 Keio University 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤
JP2011509156A (ja) * 2008-01-08 2011-03-24 イェール ユニバーシティ 血管移植片の開存性を促進するための組成物および方法
US8257936B2 (en) 2008-04-09 2012-09-04 X-Body Inc. High resolution label free analysis of cellular properties
KR20110014607A (ko) * 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
UY31861A (es) * 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
MX2010013239A (es) * 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
SG10201701323TA (en) 2008-08-18 2017-04-27 Amgen Fremont Inc Antibodies to ccr2
DK2328930T3 (da) * 2008-08-20 2015-03-30 Probiodrug Ag Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE)
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
MX2011003855A (es) * 2008-10-22 2011-12-16 Inst Research In Biomedicine Metodos para producir anticuerpos a partir de celulas plasmaticas.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
SG10201801337WA (en) 2009-03-20 2018-03-28 Amgen Inc Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8313747B2 (en) 2009-08-28 2012-11-20 Vlst Corporation Antikine antibodies that bind to multiple CC chemokines
UY32870A (es) * 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2012119756A (ru) * 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG182615A1 (en) * 2010-02-18 2012-08-30 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
TW201206473A (en) * 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
CA2831957A1 (en) * 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
RU2501017C1 (ru) * 2012-10-18 2013-12-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования невынашивания беременности в ранние сроки
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
KR20160036564A (ko) * 2013-08-06 2016-04-04 고쿠리쓰다이가쿠호진 규슈다이가쿠 유기산 중합체를 유효 성분으로 하는 암 세포의 생착 예방 또는 생착 억제를 위한 의약
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6957468B2 (ja) 2015-12-11 2021-11-02 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 最適化された患者特異的組織操作血管移植片のためのシステムおよび方法
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
US20240279704A1 (en) 2021-06-07 2024-08-22 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023122211A2 (en) * 2021-12-21 2023-06-29 Duke University Coronavirus antibodies and uses thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
ES2233978T3 (es) * 1995-09-27 2005-06-16 SHIONOGI & CO., LTD. Proteina analoga a la quimiocina de tipo cc.
JPH1160502A (ja) * 1997-08-12 1999-03-02 Teijin Ltd 脳梗塞症治療薬もしくは予防薬
WO2001089565A1 (en) 2000-05-19 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7687606B2 (en) 2010-03-30
ZA200508994B (en) 2006-09-27
EP1542724A4 (en) 2005-10-19
US7202343B2 (en) 2007-04-10
AU2003265575B2 (en) 2009-12-10
NZ542784A (en) 2008-07-31
WO2004016769A3 (en) 2004-10-14
US20070116708A1 (en) 2007-05-24
LT2005099A (en) 2006-11-27
US20070128112A1 (en) 2007-06-07
JP2005536534A (ja) 2005-12-02
JP4468172B2 (ja) 2010-05-26
WO2004016769A2 (en) 2004-02-26
US20050058639A1 (en) 2005-03-17
RS20050834A (en) 2007-12-31
IL171674A0 (en) 2009-02-11
CO6220978A2 (es) 2010-11-19
CA2496419A1 (en) 2004-02-26
EP1542724A2 (en) 2005-06-22
AU2003265575A1 (en) 2004-03-03
LT5416B (lt) 2007-04-25
MEP18108A (en) 2010-06-10
RU2005134354A (ru) 2006-06-10
RU2339647C2 (ru) 2008-11-27
US7482434B2 (en) 2009-01-27
HRP20050986A2 (en) 2006-11-30
UA87979C2 (ru) 2009-09-10

Similar Documents

Publication Publication Date Title
IS8115A (is) Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra
CY2019022I2 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2012019I2 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (en) MONOCLONAL ANTIBODY AND ITS USE
NO20044347L (no) Anti-alfavbeta6-antistoff
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
EP1614693A4 (en) PURIFICATION OF A HUMAN MONOCLONAL ANTIBODY AND A HUMAN POLYCLONAL ANTIBODY
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
NO20031642L (no) Humaniserte anti-LT-ß-R-antistoff
ATE480564T1 (de) Monoklonaler anti-mensch-tenascin-antikörper
EP1637598A4 (en) PARTIAL PEPTIDE OF CD47 AND MONOCLONAL ANTIBODY ANTI-SHPS-1
NO20032542D0 (no) Dempede anti-CD28-antistoffer og anvendelse derav
FI20011055A (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
ITPD20000192A0 (it) Anticorpi policlonali
AU2003211292A1 (en) Monoclonal antibody against human hepatoma and use thereof
ATE506966T1 (de) Humanisierte super-antikörper